📋 Indications & Clinical Dosage
*Malaria suppressive:*
ORAL: Adults: 500 mg at weekly intervals.
Children: 5 mg/kg (as chloroquine base) at weekly intervals.
*Malaria therapeutic:*
ORAL: Adults: 1000 mg initially then 500 mg daily.
*Hepatic amoebiasis:*
ORAL: Adults: 500-1000 mg daily.
*Cerebral malaria:*
BY IM OR IV INJ: Adults: 200-300 mg (chloroquine base).
💊 Mode of Administration
Administered by IV or IM injection. Stable in NS
⚠️ Precautions & Warnings
Impaired renal or hepatic function, history of epilepsy, psoriasis, porphyria, myastheniagravis, severe gastrointestinal, neurological or blood disor-ders, porphyria.Perform eye test before & during long-term therapy.
🔄 Drug Interactions
Antacids, kaolin, cimetidine, mefloquine, cyclo-sporin, rabies vaccine, anticoagulants, amiodarone, digoxin, neostigmine, pyridostigmine, moxifloxacin.
⚠️ Adverse Reactions / Side Effects
Abdominal pain, diarrhoea, headache, fever, GI distress, blood dyscrasias, skin rash (discontinue immediately), blood disorders, skin eruptions, skin-pigmentation, hair loss, blurred vision, corneal opacities, retinal damage (rare
🤰 Pregnancy & Lactation Safety
Pregnancy Risk:
use only if potential benefit outweighs risk.
Lactation / Breastfeeding:
Contraindicated or not recommended.
🧪 Compatibility & Storage Stability
Stability & Storage: Store at 25C (77F). Excursions permitted to 15C-30C (59F-86F).
📚 Official Regulatory & Clinical References
- Drug Regulatory Authority of Pakistan (DRAP): Drug Registration, S.R.O. Price Gazettes & National Essential Medicines List (NEML).
- World Health Organization (WHO): Collaborating Centre for Drug Statistics Methodology (ATC/DDD Index).
- Formulary Standards: British National Formulary (BNF) & Pakistan National Formulary (PNF) guidelines.